Quantitative translation of microfluidic transporter in vitro data to in vivo reveals impaired albumin-facilitated indoxyl sulfate secretion in chronic kidney disease.

Indoxyl sulfate (IxS), a highly albumin-bound uremic solute, accumulates in chronic kidney disease (CKD) due to reduced renal clearance. This study was designed to specifically investigate the role of human serum albumin (HSA) in IxS handling via organic anion transporter 1 (OAT1) in a microfluidic system and subsequently apply quantitative translation of in vitro data to predict extent of change in IxS renal clearance in CKD stage IV relative to healthy. Conditionally immortalized human proximal tubule epithelial cells overexpressing OAT1 were incubated with IxS (5-200 µM) in the HSA-free medium or the presence of either HSA or CKD-modified HSA. IxS uptake in the presence of HSA resulted in more than 20-fold decrease in OAT1 affinity (Km,u) and 38-fold greater in vitro unbound intrinsic clearance (CLint,u) vs. albumin-free condition. In the presence of CKD-modified albumin, Km,u increased 4-fold and IxS CLint,u decreased almost 7-fold relative to HSA. Fold-change in parameters exceeded differences in IxS binding between albumin conditions, indicating additional mechanism and facilitating role of albumin in IxS OAT-mediated uptake. Quantitative translation of IxS in vitro OAT1-mediated CLint,u predicted 60% decrease in IxS renal elimination as a result of CKD, in agreement with the observed data (80%). The findings of the current study emphasize the role of albumin in IxS transport via OAT1 and explored the impact of modifications in albumin on renal excretion via active secretion in CKD. For the first time, this study performed quantitative translation of transporter kinetic data generated in novel microfluidic in vitro system to a clinically relevant setting. Knowledge gaps and future directions in quantitative translation of renal drug disposition from microphysiological systems are discussed.

[1]  Maria M. Posada,et al.  Prediction of Transporter‐Mediated Drug‐Drug Interactions for Baricitinib , 2017, Clinical and translational science.

[2]  Chapter 1: Definition and classification of CKD , 2012, Kidney International Supplements.

[3]  Lei Zhang,et al.  Towards Quantitation of the Effects of Renal Impairment and Probenecid Inhibition on Kidney Uptake and Efflux Transporters, Using Physiologically Based Pharmacokinetic Modelling and Simulations , 2014, Clinical Pharmacokinetics.

[4]  Hugh A. Barton,et al.  Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data , 2012, Drug Metabolism and Disposition.

[5]  Bo Feng,et al.  Quantitative prediction of renal transporter-mediated clinical drug-drug interactions. , 2013, Molecular pharmaceutics.

[6]  B. Thornhill,et al.  Fight-or-flight: murine unilateral ureteral obstruction causes extensive proximal tubular degeneration, collecting duct dilatation, and minimal fibrosis. , 2012, American journal of physiology. Renal physiology.

[7]  S. Wrighton,et al.  Predictions of Cytochrome P450-Mediated Drug-Drug Interactions Using Cryopreserved Human Hepatocytes: Comparison of Plasma and Protein-Free Media Incubation Conditions , 2012, Drug Metabolism and Disposition.

[8]  Yuichi Sugiyama,et al.  The Phenomenon of Albumin-Mediated Hepatic Uptake of Organic Anion Transport Polypeptide Substrates: Prediction of the In Vivo Uptake Clearance from the In Vitro Uptake by Isolated Hepatocytes Using a Facilitated-Dissociation Model , 2018, Drug Metabolism and Disposition.

[9]  T. Meyer,et al.  Identification and Quantitative Assessment of Uremic Solutes as Inhibitors of Renal Organic Anion Transporters, OAT1 and OAT3. , 2016, Molecular pharmaceutics.

[10]  M. Jamei,et al.  Misuse of the Well-Stirred Model of Hepatic Drug Clearance , 2007, Drug Metabolism and Disposition.

[11]  D. Tibboel,et al.  A Comprehensive Analysis of Ontogeny of Renal Drug Transporters: mRNA Analyses, Quantitative Proteomics, and Localization , 2019, Clinical pharmacology and therapeutics.

[12]  F. Leblond,et al.  Effects of Chronic Renal Failure on Kidney Drug Transporters and Cytochrome P450 in Rats , 2011, Drug Metabolism and Disposition.

[13]  A. Rostami-Hodjegan,et al.  Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology , 2012, Clinical pharmacology and therapeutics.

[14]  C. Hawley,et al.  Uraemic toxins and cardiovascular disease across the chronic kidney disease spectrum: an observational study. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[15]  Malcolm Rowland,et al.  Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential , 2012, Pharmaceutical Research.

[16]  J. Gollan,et al.  Receptor for albumin on the liver cell surface may mediate uptake of fatty acids and other albumin-bound substances. , 1981, Science.

[17]  Mai-Szu Wu,et al.  Oral adsorbent AST-120 potentiates the effect of erythropoietin-stimulating agents on Stage 5 chronic kidney disease patients: a randomized crossover study. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  B. Meijers,et al.  p-cresol sulfate and indoxyl sulfate: some clouds are gathering in the uremic toxin sky. , 2017, Kidney international.

[19]  J. Wetzels,et al.  A morphological and functional comparison of proximal tubule cell lines established from human urine and kidney tissue. , 2014, Experimental cell research.

[20]  J. Jankowski,et al.  Guanidinylations of albumin decreased binding capacity of hydrophobic metabolites , 2015, Acta physiologica.

[21]  D. Stamatialis,et al.  Bioengineered kidney tubules efficiently excrete uremic toxins , 2016, Scientific Reports.

[22]  A. Galetin,et al.  Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic Clearance , 2017, Drug Metabolism and Disposition.

[23]  Key to Opening Kidney for In Vitro–In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data , 2016, The AAPS Journal.

[24]  A. Galetin,et al.  Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[25]  Murat Cirit,et al.  Integrated Gut and Liver Microphysiological Systems for Quantitative In Vitro Pharmacokinetic Studies , 2017, The AAPS Journal.

[26]  N. Bricker,et al.  The pathologic physiology of chronic Bright's disease. An exposition of the "intact nephron hypothesis". , 1997, The American journal of medicine.

[27]  K. Giacomini,et al.  PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters , 2018, Clinical pharmacology and therapeutics.

[28]  M. Otagiri,et al.  Update on the pharmacokinetics and redox properties of protein-bound uremic toxins. , 2011, Journal of pharmaceutical sciences.

[29]  N. Powe,et al.  Free Levels of Selected Organic Solutes and Cardiovascular Morbidity and Mortality in Hemodialysis Patients: Results from the Retained Organic Solutes and Clinical Outcomes (ROSCO) Investigators , 2015, PloS one.

[30]  A. Basit,et al.  Optimized Renal Transporter Quantification by Using Aquaporin 1 and Aquaporin 2 as Anatomical Markers: Application in Characterizing the Ontogeny of Renal Transporters and Its Correlation with Hepatic Transporters in Paired Human Samples , 2019, The AAPS Journal.

[31]  Hsuan-Liang Liu,et al.  Gastrointestinal-related uremic toxins in peritoneal dialysis: a pilot study with a 5-year follow-up. , 2013, Archives of medical research.

[32]  N. Powe,et al.  Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes. , 2017, Kidney international.

[33]  P. Annaert,et al.  Albumin is the main plasma binding protein for indoxyl sulfate and p‐cresyl sulfate , 2013, Biopharmaceutics & drug disposition.

[34]  R. Masereeuw,et al.  A Human Renal Proximal Tubule Cell Line with Stable Organic Anion Transporter 1 and 3 Expression Predictive for Antiviral-Induced Toxicity , 2016, The AAPS Journal.

[35]  Shiew-Mei Huang,et al.  Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration's Office of Clinical Pharmacology. , 2019, Journal of pharmaceutical sciences.

[36]  Shiew-Mei Huang,et al.  Physiologically Based Pharmacokinetic Modeling of Drug Transporters to Facilitate Individualized Dose Prediction. , 2017, Journal of pharmaceutical sciences.

[37]  Shiew-Mei Huang,et al.  Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates , 2018, Clinical pharmacology and therapeutics.

[38]  Pieter Evenepoel,et al.  A review of albumin binding in CKD. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[39]  T. Sirich,et al.  Indoxyl Sulfate—Review of Toxicity and Therapeutic Strategies , 2016, Toxins.

[40]  M. Otagiri,et al.  Renal Clearance of Endogenous Hippurate Correlates with Expression Levels of Renal Organic Anion Transporters in Uremic Rats , 2005, Journal of Pharmacology and Experimental Therapeutics.

[41]  S. Haddad,et al.  Extrapolation of the Hepatic Clearance of Drugs in the Absence of Albumin In Vitro to That in the Presence of Albumin In Vivo: Comparative Assessement of 2 Extrapolation Models Based on the Albumin-Mediated Hepatic Uptake Theory and Limitations and Mechanistic Insights. , 2018, Journal of pharmaceutical sciences.

[42]  W. van Biesen,et al.  Removal of Different Classes of Uremic Toxins in APD vs CAPD: A Randomized Cross-Over Study , 2015, Peritoneal Dialysis International.

[43]  T. Meyer,et al.  Effect of a sustained difference in hemodialytic clearance on the plasma levels of p-cresol sulfate and indoxyl sulfate. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[44]  B. Meijers,et al.  The gut–kidney axis , 2017, Pediatric Nephrology.

[45]  Aleksandra Galetin,et al.  Meta-Analysis of Expression of Hepatic Organic Anion–Transporting Polypeptide (OATP) Transporters in Cellular Systems Relative to Human Liver Tissue , 2015, Drug Metabolism and Disposition.

[46]  D. Fliser,et al.  Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[47]  M Jamei,et al.  ITC Recommendations for Transporter Kinetic Parameter Estimation and Translational Modeling of Transport‐Mediated PK and DDIs in Humans , 2013, Clinical pharmacology and therapeutics.

[48]  H. Kusuhara,et al.  Characterization of uremic toxin transport by organic anion transporters in the kidney. , 2004, Kidney international.

[49]  J. Wetzels,et al.  Uremic Toxins Inhibit Transport by Breast Cancer Resistance Protein and Multidrug Resistance Protein 4 at Clinically Relevant Concentrations , 2011, PloS one.

[50]  Bo Feng,et al.  Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach , 2017, Drug Metabolism and Disposition.

[51]  Marylore Chenel,et al.  Prediction of renal transporter‐mediated drug‐drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modelling , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[52]  Aleksandra Galetin,et al.  Use of Mechanistic Modeling to Assess Interindividual Variability and Interspecies Differences in Active Uptake in Human and Rat Hepatocytes , 2012, Drug Metabolism and Disposition.

[53]  T. Meyer,et al.  Numerous protein-bound solutes are cleared by the kidney with high efficiency , 2013, Kidney international.

[54]  Lu Gaohua,et al.  Accounting for Transporters in Renal Clearance: Towards a Mechanistic Kidney Model (Mech KiM) , 2013 .

[55]  M. Jamei,et al.  Modeling and predicting drug pharmacokinetics in patients with renal impairment , 2011, Expert review of clinical pharmacology.

[56]  Yuichi Sugiyama,et al.  Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches , 2018, Clinical pharmacology and therapeutics.

[57]  B. Kestenbaum,et al.  Diurnal and Long-term Variation in Plasma Concentrations and Renal Clearances of Circulating Markers of Kidney Proximal Tubular Secretion. , 2017, Clinical chemistry.

[58]  A. Basit,et al.  Kidney Cortical Transporter Expression across Species Using Quantitative Proteomics , 2019, Drug Metabolism and Disposition.

[59]  D. Stamatialis,et al.  Human proximal tubule epithelial cells cultured on hollow fibers: living membranes that actively transport organic cations , 2015, Scientific Reports.